Exicure, INC 8-K filings

Exicure, Inc. has appointed two new directors, Andy Yoo and Seung Ik Baik, and named Andy Yoo as Chief Restructuring Officer, following the closing of a Common Stock Purchase Agreement with HiTron Systems Inc.

Exicure has received another extension from the Nasdaq Hearings Panel to maintain its listing, with a final deadline of December 17, 2024, to demonstrate compliance.

Exicure, Inc. has entered into agreements for a $10 million equity financing and reported its third quarter 2024 financial results, highlighting a need for additional funding.

Exicure has sold its spherical nucleic acid technology, research programs, and clinical assets to Flashpoint Therapeutics for $1.5 million, with potential for future royalties.

Exicure, Inc. has received an extension from the Nasdaq Hearings Panel to maintain its listing, contingent on meeting all compliance criteria by November 14, 2024.

Exicure, Inc. has regained compliance with Nasdaq's minimum bid price requirement and executed debt-for-equity swaps with two note holders.

Exicure, Inc. will implement a 1-for-5 reverse stock split of its common stock to regain compliance with Nasdaq listing rules, effective August 27, 2024.

Exicure, Inc. has adjourned its Special Meeting of Stockholders for a second time due to insufficient votes, with the meeting rescheduled for August 20, 2024.

Exicure's Special Meeting of Stockholders was adjourned due to insufficient votes and will reconvene on August 19th to solicit additional proxies.

Exicure, Inc. announced its second quarter 2024 financial results, highlighting a significant reduction in operating expenses and a net loss of $0.6 million, while also stating that it needs additional funding in the very near term.

Exicure has been granted an extension by the Nasdaq Hearings Panel to demonstrate compliance with listing requirements by September 16, 2024, following a formal notice received on July 31, 2024.

Exicure, Inc. held its combined 2024 and 2023 Annual Meeting of Stockholders on June 28, 2024, where shareholders voted on director elections, auditor ratification, and executive compensation.

Exicure, Inc. received a notification from Nasdaq stating it is not in compliance with the minimum stockholders' equity requirement for continued listing.

Exicure, Inc. announced its first quarter 2024 financial results, highlighting a significant reduction in operating expenses and a strategic review of the company's future.

Exicure Inc. announced its 2023 financial results, revealing a significant net loss and a critical need for additional funding, while also securing a $700,000 loan from a major stockholder.

Exicure, Inc. has received a delisting notice from Nasdaq due to its failure to file its 2023 Form 10-K and Q1 2024 Form 10-Q, and not holding its 2023 annual meeting.

Exicure, Inc. announced its third quarter 2023 financial results, revealing a significant decrease in cash reserves and the need for immediate additional funding while exploring strategic alternatives.

Exicure, Inc. received a Nasdaq notice of non-compliance for failing to file its annual report, putting its listing status at risk.

Exicure, Inc. has entered into a patent license agreement with Bluejay Therapeutics, granting Bluejay exclusive rights to develop cavrotolimod for the treatment of hepatitis.

Exicure, Inc. received a notification from Nasdaq for failing to hold its annual shareholder meeting within the required timeframe, potentially leading to delisting.